X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration includes a license to ALT-2023, a broadly active nucleoside analogue that is late stage preclinical development, as well as options to additional compounds addressing RNA viruses.
Lead Product(s): ALT-2023
Therapeutic Area: Infections and Infectious Diseases Product Name: ALT-2023
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Altesa Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 10, 2022
Details:
Ridgeback has exclusively licensed DRIVE's EIDD-2801 and will be responsible for advancing it through clinical development and ensuring that EIDD-2801 is available during current pandemic.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ridgeback
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 23, 2020
Details:
DRIVE is developing the compound, designated EIDD-2801, which has shown efficacy against other coronaviruses such as SARS-CoV and MERS-CoV.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
